Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4552W HIGH $14.80
Volume
10.71 K
Value Traded
66.32 K
Short % Float
0.05%
-4.52%Week
-40.63%1 Month
-54.87%3 Month
-33.6%6 Month
-93.87%5 Year
-93.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.31 M
EPS (TTM)
-0.17
P/E Ratio
-
Ent. Value
-61.15 K
Total Shares
7.00 M
Float Shares
5.89 M
Insiders
23.01%
Institutions
0.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CUPR Catalyst Timeline
Dated clinical, regulatory and corporate events for Cuprina Holdings (Cayman) Limited
Past FDA Catalysts and PDUFA Decisions
How CUPR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Cuprina Holdings (Cayman) Limited is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CUPR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CUPR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CUPR for Q2 2026. | ||||
CUPR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CUPR ranks across every disease it competes in
Competitive Position is a premium feature
See how CUPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCUPR News
CUPR▼ -5.1%on this news· ran to -22% by day 3
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
Cuprina Holdings has announced its acquisition of East Coast Podiatry and Orchard Clinic for approximately S$4.0 million. The target group generated an unaudited revenue of S$9.1 million and EBITDA of S$1.2 million for FY2025. This acquisition aims to enhance Cuprina's healthcare platform, particularly in wound care and women's wellness services, with expected completion by November 1, 2026.
Read more →CUPR▲ +13.4%on this news· ran to +27% by day 1shared move
Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering
Cuprina Holdings (Cayman) Limited successfully closed the sale of an additional 648,373 Class A ordinary shares, raising approximately $745,629. This follows a public offering that generated total gross proceeds of around $5.7 million. The company plans to utilize the funds for expansion, research and development, and general corporate purposes.
Read more →CUPRCuprina Holdings (Cayman) Limited Announces Closing of Public Offering
Cuprina Holdings (Cayman) Limited has successfully closed a public offering of 4,322,489 Class A Ordinary Shares, raising approximately $4.97 million. The company plans to use the proceeds for expansion, research and development, and general corporate purposes. The offering follows recent FDA clearance for its MEDIFLY Maggots™ product, enhancing its wound care pipeline.
Read more →CUPR▼ -45.4%on this newsshared move
Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering
Cuprina Holdings (Cayman) Limited has announced the pricing of a public offering of 4,322,489 shares at $1.15 per share, aiming to raise approximately $4.97 million. The offering includes a 45-day option for underwriters to purchase additional shares, potentially increasing total proceeds to $5.72 million. The offering is set to close on or about September 17, 2026, pending customary conditions.
Read more →CUPR▲ +111.8%on this news
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
Cuprina Holdings has received FDA 510(k) clearance for MEDIFLY Maggots™, marking it as the first U.S. product using Lucilia cuprina for maggot debridement therapy. This product is intended for treating non-healing necrotic wounds and is expected to be available to U.S. wound-care providers soon. The clearance positions Cuprina uniquely in the market, allowing for broader international regulatory pursuits.
Read more →CUPR▲ +64.7%on this news· ran to +249% by day 1shared move
Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements
Cuprina Holdings (Cayman) Limited has announced that it has regained compliance with Nasdaq Capital Markets Listing Requirements as of June 11, 2026. This follows a previous notification of non-compliance due to its stock price falling below $1.00 for 30 consecutive days. The company has successfully appealed the delisting determination, and its shares will continue to be traded on Nasdaq.
Read more →CUPR▼ -27.3%on this news
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
Cuprina Holdings has completed a reverse stock split and requested a hearing with the Nasdaq Hearings Panel to appeal a delisting determination due to non-compliance with the minimum bid price requirement. The company aims to regain compliance and maintain its Nasdaq listing. A hearing request will stay the suspension of its securities pending the Panel's decision.
Read more →CUPRCuprina Holdings announces 1-for-8 Share Consolidation
Cuprina Holdings announced a 1-for-8 share consolidation effective May 27, 2026, to comply with Nasdaq listing requirements. This move was approved by the board and shareholders, aiming to enhance the company's financial position. The consolidation will not change shareholders' percentage interests, although fractional shares will be rounded up.
Read more →CUPRCuprina Holdings (Cayman) Limited (Incorporated in the Cayman Islands with limited liability) Notice of Annual General Meeting of Shareholders To Be Held on
Cuprina Holdings (Cayman) Limited has announced its annual general meeting (AGM) scheduled for May 14, 2026, at 9:00 p.m. local time. Shareholders will vote on several key proposals, including the appointment of auditors and the re-election of current directors. Additional proposals include changes to share capital and voting rights, as well as an employee equity incentive plan. The meeting will be accessible to eligible attendees both in person and via live webcast.
Read more →CUPR▲ +8.1%on this news
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
Cuprina Holdings has achieved a significant regulatory milestone with the Saudi Food and Drug Authority's classification of its MEDIFLY product as a Medical Device-Drug combination. This classification enables the company to proceed with commercial distribution across Saudi Arabia. Additionally, Cuprina has expanded its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, enhancing its clinical governance and strategic direction.
Read more →CUPR▼ -6.6%on this news
CUPRINA HOLDINGS (CAYMAN) LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Financial Statements: Unaudited Condensed Consolidated Balance Sheets as of
Cuprina Holdings (Cayman) Limited released its index to unaudited condensed consolidated financial statements. However, the document contains a significant amount of technical terminology without presenting specific financial metrics or insights. This lack of clarity could lead to uncertainties regarding the company's financial status. Stakeholders may find it challenging to assess the company’s performance based solely on the provided information.
Read more →CUPR▼ -6.6%on this news
Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth
Cuprina Holdings (Cayman) Limited reported its financial results for the six months ending June 30, 2025, showing a revenue decline and an increase in net loss compared to the previous year. Despite these setbacks, the company highlighted achievements in product diversification and geographical expansion, including the construction of an IVF media production facility and a partnership for medical waste recycling technology. For 2026, Cuprina anticipates multiple revenue streams and intends to strengthen its leadership to facilitate growth and long-term profitability.
Read more →CUPRCuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Cuprina Holdings (Cayman) Limited has received a notification from Nasdaq regarding noncompliance with minimum bid price requirements. The company has 180 days to regain compliance by maintaining a bid price of at least $1 per share. If compliance is not achieved, Cuprina may seek additional time or face delisting. The shares will continue to trade as usual during this period.
Read more →CUPRCuprina forms Joint Venture Company with Aiodine Laboratory to Develop and Market Novel Iodine-based Solution as New Wound Care Therapy
Cuprina Holdings has announced a joint venture with Aiodine Laboratory to develop a novel iodine-based disinfectant solution for wound care. The companies plan to initiate clinical studies in 2026, focusing on antiseptic applications and personal care. Early studies indicated promising results in wound healing without toxicity. With the growing global wound care market, this collaboration could enhance treatment options for chronic wounds.
Read more →CUPR▲ +19.1%on this news
Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies
Cuprina Holdings has signed a Memorandum of Understanding with Singapore Biowaste Solutions to integrate its medical waste recycling technology into SBS's facility. This collaboration aims to reduce reliance on incineration and enhance recycling efficiency while developing revenue-sharing models. The technology, developed over 20 years, is expected to comply with Singapore's environmental standards and commence operations by the end of 2026.
Read more →CUPRCuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
Cuprina Holdings will present at the Skyline Signature Series on October 8, 2025, at 11:00 AM ET. The event will be interactive, allowing investors to ask questions in real-time. This initiative aims to enhance communication between the company and financial professionals. Pre-registration is required for attendees.
Read more →CUPR▲ +12.2%on this news· ran to +159% by day 1
Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
Cuprina Holdings has acquired exclusive rights to a pioneering medical waste recycling technology in Southeast Asia, developed under UNIDO and GEF oversight. This technology offers a sustainable alternative to incineration, sterilizing and recycling medical waste into valuable materials. Cuprina plans to establish a facility in Singapore and expand operations across the region, addressing growing environmental concerns.
Read more →CUPR▲ +9.2%on this news· ran to -20% by day 1
Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
Cuprina Holdings has addressed recent stock market volatility, reassuring shareholders of its operational health and commitment to advancing its biotherapeutic pipeline. The company reported no known operational issues causing the volatility and highlighted ongoing regulatory milestones, including FDA submissions. Cuprina emphasizes transparency and integrity in its communications with stakeholders.
Read more →CUPR▲ +5%on this news
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
Cuprina Holdings has appointed Dr. Ronald Sherman as Medical and Scientific Director, effective September 2025. The company has also secured a license to market FDA-approved medical maggots for debridement therapy in the U.S. This strategic move aims to enhance clinical expertise and regulatory support for their innovative therapies, with a focus on expanding market presence.
Read more →About Cuprina Holdings (Cayman) Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next CUPR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime